Cargando…
Adamantinomatous craniopharyngioma associated with a compromised blood–brain barrier: patient series
BACKGROUND: Adamantinomatous craniopharyngioma (ACP) is a highly morbid adult and pediatric brain tumor derived from epithelial remnants of the craniopharyngeal canal (Rathke’s pouch), which gives rise to the anterior pituitary gland. Standard therapy includes maximal safe resection with or without...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association of Neurological Surgeons
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245763/ https://www.ncbi.nlm.nih.gov/pubmed/35854837 http://dx.doi.org/10.3171/CASE2150 |
_version_ | 1784738815484624896 |
---|---|
author | Prince, Eric W. Hoffman, Lindsey M. Vijmasi, Trinka Dorris, Kathleen McWilliams, Jennifer A. Jordan, Kimberly R. Mirsky, David M. Hankinson, Todd C. |
author_facet | Prince, Eric W. Hoffman, Lindsey M. Vijmasi, Trinka Dorris, Kathleen McWilliams, Jennifer A. Jordan, Kimberly R. Mirsky, David M. Hankinson, Todd C. |
author_sort | Prince, Eric W. |
collection | PubMed |
description | BACKGROUND: Adamantinomatous craniopharyngioma (ACP) is a highly morbid adult and pediatric brain tumor derived from epithelial remnants of the craniopharyngeal canal (Rathke’s pouch), which gives rise to the anterior pituitary gland. Standard therapy includes maximal safe resection with or without radiation therapy. Systemic antitumor therapy remains elusive. Immune-related paracrine signaling involving the interleukin-6 receptor (IL-6R) may contribute to ACP pathogenesis. Tocilizumab, a recombinant humanized monoclonal antibody against IL-6R, is approved by the US Food and Drug Administration but does not cross an intact blood–brain barrier. OBSERVATIONS: In a phase 0 trial design, a single dose of tocilizumab was delivered intravenously before clinically indicated surgical intervention in 3 children with ACP. The presence of tocilizumab was assayed in plasma, tumor tissue, tumor cyst fluid, and cerebrospinal fluid (n = 1) using a novel enzyme-linked immunosorbent assay. Tocilizumab reached ACP tumor tissue and/or cyst fluid after one systemic dose in every patient. LESSONS: This finding helps explain extant data that indicate tocilizumab may contribute to ACP therapy. It further indicates that ACP does not reside behind an intact blood–brain barrier, dramatically broadening the range of potential antitumor therapies against this tumor. This has substantial implications for the design of future clinical trials for novel therapies against ACP in both children and adults. |
format | Online Article Text |
id | pubmed-9245763 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Association of Neurological Surgeons |
record_format | MEDLINE/PubMed |
spelling | pubmed-92457632022-07-18 Adamantinomatous craniopharyngioma associated with a compromised blood–brain barrier: patient series Prince, Eric W. Hoffman, Lindsey M. Vijmasi, Trinka Dorris, Kathleen McWilliams, Jennifer A. Jordan, Kimberly R. Mirsky, David M. Hankinson, Todd C. J Neurosurg Case Lessons Case Lesson BACKGROUND: Adamantinomatous craniopharyngioma (ACP) is a highly morbid adult and pediatric brain tumor derived from epithelial remnants of the craniopharyngeal canal (Rathke’s pouch), which gives rise to the anterior pituitary gland. Standard therapy includes maximal safe resection with or without radiation therapy. Systemic antitumor therapy remains elusive. Immune-related paracrine signaling involving the interleukin-6 receptor (IL-6R) may contribute to ACP pathogenesis. Tocilizumab, a recombinant humanized monoclonal antibody against IL-6R, is approved by the US Food and Drug Administration but does not cross an intact blood–brain barrier. OBSERVATIONS: In a phase 0 trial design, a single dose of tocilizumab was delivered intravenously before clinically indicated surgical intervention in 3 children with ACP. The presence of tocilizumab was assayed in plasma, tumor tissue, tumor cyst fluid, and cerebrospinal fluid (n = 1) using a novel enzyme-linked immunosorbent assay. Tocilizumab reached ACP tumor tissue and/or cyst fluid after one systemic dose in every patient. LESSONS: This finding helps explain extant data that indicate tocilizumab may contribute to ACP therapy. It further indicates that ACP does not reside behind an intact blood–brain barrier, dramatically broadening the range of potential antitumor therapies against this tumor. This has substantial implications for the design of future clinical trials for novel therapies against ACP in both children and adults. American Association of Neurological Surgeons 2021-05-10 /pmc/articles/PMC9245763/ /pubmed/35854837 http://dx.doi.org/10.3171/CASE2150 Text en © 2021 The authors https://creativecommons.org/licenses/by-nc-nd/4.0/CC BY-NC-ND 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). |
spellingShingle | Case Lesson Prince, Eric W. Hoffman, Lindsey M. Vijmasi, Trinka Dorris, Kathleen McWilliams, Jennifer A. Jordan, Kimberly R. Mirsky, David M. Hankinson, Todd C. Adamantinomatous craniopharyngioma associated with a compromised blood–brain barrier: patient series |
title | Adamantinomatous craniopharyngioma associated with a compromised blood–brain barrier: patient series |
title_full | Adamantinomatous craniopharyngioma associated with a compromised blood–brain barrier: patient series |
title_fullStr | Adamantinomatous craniopharyngioma associated with a compromised blood–brain barrier: patient series |
title_full_unstemmed | Adamantinomatous craniopharyngioma associated with a compromised blood–brain barrier: patient series |
title_short | Adamantinomatous craniopharyngioma associated with a compromised blood–brain barrier: patient series |
title_sort | adamantinomatous craniopharyngioma associated with a compromised blood–brain barrier: patient series |
topic | Case Lesson |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245763/ https://www.ncbi.nlm.nih.gov/pubmed/35854837 http://dx.doi.org/10.3171/CASE2150 |
work_keys_str_mv | AT princeericw adamantinomatouscraniopharyngiomaassociatedwithacompromisedbloodbrainbarrierpatientseries AT hoffmanlindseym adamantinomatouscraniopharyngiomaassociatedwithacompromisedbloodbrainbarrierpatientseries AT vijmasitrinka adamantinomatouscraniopharyngiomaassociatedwithacompromisedbloodbrainbarrierpatientseries AT dorriskathleen adamantinomatouscraniopharyngiomaassociatedwithacompromisedbloodbrainbarrierpatientseries AT mcwilliamsjennifera adamantinomatouscraniopharyngiomaassociatedwithacompromisedbloodbrainbarrierpatientseries AT jordankimberlyr adamantinomatouscraniopharyngiomaassociatedwithacompromisedbloodbrainbarrierpatientseries AT mirskydavidm adamantinomatouscraniopharyngiomaassociatedwithacompromisedbloodbrainbarrierpatientseries AT hankinsontoddc adamantinomatouscraniopharyngiomaassociatedwithacompromisedbloodbrainbarrierpatientseries |